Find Academic Supervisors

Jean-Michel Dogné is a full Professor at the Faculty of Medicine, University of Namur, where he leads research in clinical pharmacology and toxicology. He is affiliated with several key research centers including the Namur Medicine & Drug Innovation Center, the Namur Thrombosis and Hemostasis Center, and the Namur Nanosafety Center. His work is integral to the Namur Research Institute for Life Sciences and he actively contributes to EU-level pharmacovigilance through his role in the EMA's PRAC committee. Education: Doctor of Pharmacy, Université de Liège (2000), Thesis: Drug design and development His research focuses on anticoagulant therapy, thrombosis, drug safety, and personalized medicine , with strong emphasis on clinical applications in cancer and infectious diseases. He has led major projects such as COVILAB (on COVID-19) and studies on BCR-ABL inhibitors in leukemia. His work often involves systematic reviews, meta-analyses, and biomarker discovery, contributing to evidence-based medicine. The 15 most recent publications reflect a sustained focus on thrombosis in oncology, pharmacovigilance, anticoagulants, and pandemic research , with increasing integration of regulatory science and model-informed drug development. His work spans clinical trials, laboratory investigations, crystallography, and public health policy , demonstrating a multidisciplinary approach to pharmaceutical innovation. Scientific Awards: Prix Léo Pharma Cancer & Thrombosis (2017) Jean-Michel Dogné has supervised over 40 students and researchers, contributing significantly to training the next generation of clinical pharmacologists. He has secured numerous national and international grants, particularly in the areas of drug safety and thrombosis. His collaborative network is extensive, involving institutions across Europe and participation in EU-level regulatory bodies. He is a key member of the Clinical Pharmacology Research Group and leads major initiatives such as the MP-EMA project. His team operates within state-of-the-art facilities at the University of Namur, focusing on translational research from bench to bedside.

• Clinical Pharmacology
• Pharmacovigilance
• Thrombosis and Hemostasis
• +7 more

Peter Verwilst is an Associate Professor at the Medicinal Chemistry division of the Rega Institute for Medical Research , part of KU Leuven 's Department of Pharmaceutical and Pharmacological Sciences. He leads projects in allosteric modulation of enzyme targets , fluorescent markers for neurodegenerative diseases , and novel antimicrobial development , particularly focusing on Gram-negative bacteria and HIV-related therapies. His research integrates computational modeling , chemical synthesis , and fluorescent probe design . He supervises PhD students including Margaux Billen , Eline Goffin , and Radu Bulai , and collaborates with institutions like Masaryk University and the Institut Pasteur de Lille. Current projects explore CCR5 signaling modulators , PurK inhibitors , and DNA-Encoded Libraries for P. aeruginosa antibiotics. Scientific awards include supporting students like Radu Bulai in obtaining FWO PhD Fellowships . His teaching includes Organische chemie I & II and Medicinale chemie courses. The lab recently celebrated securing a C1 grant and welcomes international collaborations.

• Medicinal Chemistry
• Allosteric Modulation of Enzyme Targets
• Fluorescent Markers for Neurodegenerative Diseases
• +5 more

Gregory Ehx is a Researcher at the University of Liège's GIGA institute, specifically within the GIGA-I3 (Infection Immunity and Inflammation) research unit of the Faculty of Medicine. He leads the Translational Immunology and Leukemia research team in the Hematology Laboratory, focusing on understanding immune recognition of acute myeloid leukemia (AML) cells and developing novel immunotherapies. Dr. Ehx's research centers on how leukemia cells are recognized by immune cells and how they escape immune surveillance. His team studies the interaction between T cells and malignant cells, particularly focusing on MHC-presented peptides and immuno-inhibitory molecules like PD-L1 and CD47 expressed by AML cells. Key research areas include: Development of cancer immunotherapies for permanent leukemia eradication Maximizing immune recognition of chemotherapy-surviving cancer cells Identification of tumor-specific immunogenic peptides Understanding mechanisms of chemotherapy resistance His publication record demonstrates significant contributions to cancer immunology, with a focus on proteogenomics and computational approaches to identify actionable tumor antigens. Recent work has revealed how endogenous retroelements generate immunogenic peptides in AML and how autophagy affects immune recognition of cancer cells treated with 5-azacytidine. Scientific recognition includes: FNRS Research associate mandate (2023) Comte de Launoit Prize Dr. Ehx secured funding through the FNRS Research associate program to pursue his ambitious research program on developing vaccines targeting chemotherapy-resistant AML cells. His work on the BamQuery computational tool has enabled identification of tumor-specific MHC peptides, forming the basis for potential cancer vaccine development. His research has implications beyond AML, potentially benefiting treatment of other cancers including colon, lung, and breast cancer. The researcher leads his team within the Hematology Laboratory at GIGA, building on collaborations with researchers at the Institute for Research in Immunology and Cancer (IRIC) in Canada and other international partners. His laboratory combines wet-lab immunology with computational approaches to tackle the challenge of cancer immunotherapy.

• Translational Immunology
• Leukemia Research
• Acute Myeloid Leukemia
• +5 more

Christina Campo, PhD, is a researcher affiliated with the Faculty of Psychology and Educational Sciences in Brussels, Belgium. Her work intersects medical research and genetic studies, particularly focusing on hematological disorders and their molecular underpinn'the faculty affiliation suggests broader academic engagement. Her research includes contributions to understanding the genetic links between immunoglobulin light-chain amyloidosis and multiple myeloma, as evidenced by her 2014 publication in Leukemia . While her specific role within the faculty is not detailed, her research output highlights cross-disciplinary expertise in medicine and genetics. As of the provided data, Christina Campo has not disclosed email contact information or scientific awards. Her academic activities are primarily reflected in her single peer-reviewed publication, which explores the genetic basis of blood-related diseases.

• Medicine
• Genetics
• Hematology
• +3 more

Niels Vandewalle is an active researcher at the Vrije Universiteit Brussel (VUB), affiliated with the Basic (bio-) Medical Sciences department within the Faculty of Medicine and Pharmacy. His work focuses on oncology, immunology, and hematological malignancies, particularly Acute Myeloid Leukemia (AML) and Multiple Myeloma. He leads projects on AXL targeting using single-domain antibodies and small molecule inhibitors, with applications in diagnosis and therapy. Vandewalle has supervised research by Kim De Veirman and collaborates extensively with teams in Belgium and internationally. Research interests include tumor microenvironment dynamics, immune evasion mechanisms, and drug resistance in cancer. His recent studies explore adrenergic signaling's role in myeloma progression and the therapeutic potential of anti-CD40 agonists in activating dendritic cells. Vandewalle has received the Best Poster Presentation award (2024) and contributed to datasets published in high-impact repositories like Zenodo and NCBI GEO. He actively participates in academic events, organizing charity quizzes and PhD symposiums. His projects (e.g., ANI400 and FWOSB110) emphasize translational research, aiming to bridge basic science and clinical applications in leukemia treatment.

• Hematology
• Oncology
• Immunology
• +6 more

Sarah-Maria Fendt is a Professor of Oncology at KU Leuven and Principal Investigator at the VIB Center for Cancer Biology. She serves as Head of the Laboratory of Cellular Metabolism and Metabolic Regulation and holds multiple leadership positions including membership in the Council of the Faculty of Medicine, the Council of the Department of Oncology, and the Research Council. Her primary research focuses on understanding the role of metabolism in driving cancer metastasis formation and defining metabolic regulation principles that enable cancer cell plasticity and heterogeneity. Dr. Fendt's lab applies cutting-edge single cell and spatial multi-omics technologies to study the interplay between cancer cells and their metabolic environment using pre-clinical mouse models and patient samples. Her research is funded by multiple national and international grants, including recent projects on metabolic vulnerabilities in acute myeloid leukemia, single-cell resolution in mass spectrometry imaging, and metabolic changes in metastatic liver. Dr. Fendt's publication record demonstrates significant contributions to cancer metabolism research, with recent articles in top journals including Nature, Nature Cancer, and Cell Reports. Her work reveals how metabolic adaptations drive metastasis through mechanisms including aspartate signaling, lipid metabolism, and metabolite-induced immune suppression. She has established herself as a leader in translating metabolic discoveries into potential therapeutic approaches. EMBO Gold Medal (2020) EMBO member (since 2022) Francqui-Collen prize (2023) 51st Léopold Griffuel award (2023) AACR award for Outstanding Achievement in Basic Cancer Research (2024) Dr. Fendt actively mentors the next generation of cancer researchers, with several students and postdocs presenting their work at international conferences. She recently completed a sabbatical at Peter MacCallum Cancer Centre in Australia working with Mark Dawson's laboratory. Her lab is a member of multiple research centers including the VIB-KU Leuven Center for Cancer Biology, LISCO (KU Leuven Institute for Single Cell Omics), and LKI (KU Leuven Cancer Institute).

• Cancer Metabolism
• Metastasis Biology
• Cellular Metabolism
• +4 more

Kim De Veirman is a postdoctoral researcher and part-time Assistant Professor (10%) at the Free University of Brussels (VUB), affiliated with the Department of Hematology and Immunology (HEIM). Her work focuses on translational oncology, particularly targeting residual disease in multiple myeloma through nanobody-based therapies. Primary institution: Free University of Brussels (VUB) Collaborations: Garvan Institute (Sydney), Profs Nick Devoogdt, Matthias D'Huyvetter, Peter Croucher Research Interests : Kim's research centers on multiple myeloma , with specific emphasis on: Targeting residual cancer cells using AXL- and CS1-specific nanobodies Investigating drug resistance mechanisms in the bone marrow microenvironment Developing targeted radionuclide therapy (TRNT) and nanoCAR-T cell approaches Studying myeloid-derived suppressor cells (MDSCs) , cancer-associated fibroblasts , and mesenchymal stromal cells in tumor progression Scientific Awards : ASH Abstract Achievement Award (2014, 2019) FWO Fellowship (2016) Best Poster Presentation (2024, 2025) Research Trends : Her recent publications highlight advancements in nanobody-based targeting , epigenetic regulation (e.g., MAT2A, DNMT3B), and stroma-tumor interactions . Key collaborations include work on 3D super-resolution imaging and immune microenvironment mapping . Grants and Projects : Current projects include RAPTOR (bioreactors for protein translation), NANO-AXL (targeting AXL in myeloma), and 3D-CELLMAP (cellular interactions in tissues). She has secured funding from the FWO and participates in EU FP7 OVER-MyR research.

• Multiple Myeloma
• Acute Myeloid Leukemia
• Nanobodies
• +7 more

Karen Pittois is a Lecturer and researcher at AP University College since 2006, specializing in Biomedical Laboratory Technology and Chemistry programs. She teaches biochemistry, molecular genetics, gene technology, immunology, immunopathology, and supervises biochemical lab practicums for third-year students. She holds a PhD in Biochemistry from the University of Antwerp (1999) and previously worked as a Senior Scientist at Galápagos (2006–2013). Education: PhD in Biochemistry, University of Antwerp (1999) Research Focus: Development of diagnostic tools and molecular techniques, including digital droplet PCR (ddPCR) for chronic eosinophilic leukemia, multiplex PCR for gene fusion detection, and 3D cell culture systems for drug testing (e.g., TOAST project). Her expertise spans ELISA, real-time PCR, molecular biology, and biochemical techniques. Key Projects: ddPCR (2019–2020): Novel diagnostic test for chronic eosinophilic leukemia. Multiplex (2021–2023): Detection of FIP1L1-PDGFRA fusion gene in hypereosinophilia. Breakpoints (2020–2021): Analysis of fusion gene breakpoints. TOAST (2016–2018): 3D cell culture system for drug efficacy testing. CIP (2013–2017): Cell growth in porous hydrogels. Advising & Labs: Supervises biochemical laboratory practicums and coordinates research projects. Active in lab development for biomedical applications.

• Molecular Biology
• Biochemistry
• Biomedical Research
• +3 more

Nikolay Tumanov is a Researcher at the University of Namur , affiliated with the Namur Institute of Structured Matter and Namur Research Institute for Life Sciences . He specializes in crystallography, boron chemistry, and organic-inorganic hybrid materials, with a focus on atropisomerism, anion binding, and pharmaceutical cocrystallization. His work spans powder X-ray diffraction , anticancer drug development , and supramolecular systems .

• Crystal Structure
• X-ray Diffraction
• Boron Chemistry
• +5 more

Dr. Adeline WANNEZ is a researcher at the Faculty of Medicine, University of Namur, specializing in thrombosis mechanisms and extracellular vesicle biology. Her work bridges biomedical science with clinical hematology. Doctorate in Biomedical and Pharmaceutical Sciences (2018) Master in Biomedicine (2014) Research Interests: Focuses on blood coagulation risks , extracellular vesicle dynamics , and hematological malignancies . Key methodologies include flow cytometry and clot-based assays . Her publications (2016-2020) cover thrombosis in leukemia patients microRNA biomarkers in lymphoma procoagulant activity of blood products flow cytometry protocols for vesicle analysis

• Thrombosis
• Extracellular Vesicles
• Hematology
• +6 more

Jona Van der Straeten is a Researcher in Clinical Biology at the Translational Oncology Research Center of Vrije Universiteit Brussel (VUB), specializing in translational hematology research. Her work primarily focuses on developing and validating molecular diagnostic techniques for monitoring minimal residual disease in hematological malignancies. Her research interests center on translational hematology with particular expertise in minimal residual disease monitoring in acute lymphoblastic leukemia and multiple myeloma. She utilizes advanced molecular techniques including conventional allele-specific oligonucleotide (ASO)-PCR and Next-Generation sequencing (NGS) to develop more sensitive detection methods for cancer cells that remain after treatment. Analysis of her publications reveals a consistent research trajectory in cancer diagnostics, with increasing focus on next-generation sequencing technologies for minimal residual disease detection. Her work spans both lymphoid malignancies (acute lymphoblastic leukemia) and plasma cell disorders (multiple myeloma), with recent publications emphasizing the clinical application of NGS-based approaches. Van der Straeten actively participates in the hematology research community through conference presentations and collaborations. Her recent activities include presentations at the 2022 conferences on liquid biopsy for myeloma detection and NGS-based MRD strategies for leukemia and myeloma.

• translational research
• hematology
• minimal residual disease monitoring
• +6 more

Christelle Orlando serves as an Unpaid guest professor (mapped to Visiting Professor) in the School of Clinical Sciences and Researcher in Clinical Biology at Vrije Universiteit Brussel, with continuous scientific collaboration at Universitair Ziekenhuis Brussel's Hemostasis lab since 2005. She oversees routine and specialized coagulation testing while contributing to translational research through the Translational Oncology Research Center affiliation. Her academic credentials include a Master's degree in Medical Sciences (2005) and PhD in Medical Sciences (2021), both from Vrije Universiteit Brussel, focusing on minimal residual disease detection in pediatric leukemia and novel insights into inherited antithrombin deficiency respectively. Dr. Orlando's research centers on inherited thrombophilia , with specialized expertise in antithrombin deficiency mechanisms and diagnostics. She investigates genotype-phenotype correlations in coagulation disorders, develops laboratory validation protocols, and examines clinical implications of rare mutations like the Budapest 3 variant. Her work bridges molecular pathology with clinical hemostasis practice through rigorous diagnostic assay evaluation. Recent publications demonstrate evolving expertise from case-based mutation analysis toward comprehensive diagnostic methodology. Her 2024-2025 work shows increasing emphasis on analytical validation of hemostasis instruments and standardization of antithrombin testing , reflecting field-wide shifts toward precision diagnostics in thrombophilia. Her contributions have earned significant recognition: Paul Capel Prize (2010 and 2011) Prijs Edmond Secq en André Houssiau 2022 for inherited bleeding disorders research (awarded 2023) Dr. Orlando actively mentors next-generation researchers, supervising Master's theses like Bouteille, S.P.'s 2022 work on protein C deficiency genotype-phenotype correlations. Her professional engagements include conference chairing (Werfen SAC Meeting Benelux 2024), invited lectures on thrombophilia testing standardization, and peer review for Haemophilia journal, demonstrating leadership in hemostasis education and quality assurance. Within UZ Brussel's Hemostasis lab, she leads specialized coagulation testing initiatives while collaborating with the Translational Oncology Research Center on projects intersecting coagulation disorders and cancer-related thrombosis, driving innovation in diagnostic protocols for complex clinical scenarios.

• Inherited Thrombophilia
• Antithrombin Deficiency
• Coagulation Disorders
• +3 more

Lucie Caramelle is a Researcher at the Namur Research Institute for Life Sciences , affiliated with the Laboratory of Cellular Biochemistry and Biology . Her work focuses on cellular biochemistry, particularly in sterol metabolism, cholesterol transport, and the role of oxysterol-binding protein (OSBP) in retrograde trafficking. Recent research (2024) highlights her contributions to understanding how OSBP inhibition affects Golgi degradation and leukemic dependencies, with publications in Nature Chemical Biology . Collaborations include international teams in biochemistry and molecular biology. Her studies intersect lipid transport mechanisms and cancer biology, particularly leukemia, using chemical biology approaches to target OSBP pathways.

• Biochemistry
• Molecular Biology
• Cell Biology
• +3 more

Francois Mullier is a Research Professor at the University of Namur, specializing in Clinical Pharmacology and Toxicology. He actively contributes to thrombosis and hemostasis research through the Namur Thrombosis and Hemostasis Center and Namur MEdicine & Drug Innovation Center. His work focuses on anticoagulant therapy, coagulation assays, and drug-induced thrombosis. Key Affiliations : University of Namur, Namur Thrombosis and Hemostasis Center, Namur MEdicine & Drug Innovation Center Research Themes : Anticoagulant pharmacology, Thrombosis mechanisms, Clinical hemostasis testing Dr. Mullier’s recent publications highlight his expertise in evaluating new anticoagulant agents like asundexian, analyzing preanalytical variables in fibrin metabolism testing, and assessing the sustainability of laboratory practices. His work bridges pharmacology and clinical hematology, emphasizing drug safety and diagnostic accuracy. Scientific contributions include a 2017 Prix Léo Pharma Cancer & Thrombosis for his research on tyrosine kinase inhibitors. He has supervised projects on drug-induced thrombosis and coagulation assay validation, collaborating with institutions like Catholic University Louvain (UCLouvain). His research outputs span Research and Practice in Thrombosis and Haemostasis , International Journal of Laboratory Hematology , and The Journal of Applied Laboratory Medicine .

• Thrombosis
• Hemostasis
• Clinical Pharmacology
• +4 more

Koen Debackere is an Assistant Professor at KU Leuven, affiliated with the Faculty of Medicine and the Department of Oncology. He conducts research in the Laboratory of Experimental Hematology, focusing on hematological malignancies and immunotherapy. His work bridges basic science and clinical applications, with emphasis on T-cell lymphomas and acute myeloid leukemia. His research interests encompass the genetic drivers of peripheral T-cell lymphomagenesis, the development of immunotherapies for hematological cancers, and the characterization of the tumor microenvironment. He is particularly interested in targeting mutant NPM1 in acute myeloid leukemia with T-cell receptor-like chimeric antigen receptors and understanding the dual role of T cells in hematology as both therapeutic targets and allies. His research often involves molecular characterization and the identification of druggable targets through projects spanning CAR-T cell therapy, ATMP regulatory frameworks, and lymphoma pathogenesis. Recent publications reveal a strong translational focus on hematological malignancies, particularly T-cell lymphomas and acute myeloid leukemia, with emerging work in technology transfer and innovation management. This dual expertise bridges laboratory discoveries in genetic drivers and signaling pathways to therapeutic applications and research commercialization. Debackere serves as a doctoral supervisor, evidenced by his 2022 thesis supervision on peripheral T-cell lymphomagenesis. He leads significant research funding initiatives including: Promotor of "Improving patient care through reliable clinical immune biomarkers across the CAR-T cell trajectory" (2025-2029) Promotor of "Opening the door for immunotherapy in acute myeloid leukemia: targeting mutant NPM1" (2025-2026) Promotor of "The Dual Nature of T Cells in Hematology" (2024-2026) Co-promotor of "Increasing ATMP regulatory awareness" (2024-2028) Co-promotor of "Molecular characterization of hyperactive T cell receptor signaling" (2023-2027) He is an integral member of the Laboratory of Experimental Hematology, which operates within KU Leuven's Department of Oncology. The lab employs multidisciplinary approaches combining genomic analysis, molecular biology, and clinical hematology to investigate lymphoma pathogenesis and develop novel immunotherapies.

• Hematology
• Oncology
• Immunotherapy
• +6 more